Total Payments
$44,792
2024 Payments
$17,086
Companies
5
Transactions
43
Medicare Patients
190
Medicare Billing
$24,698
Payment Breakdown by Category
Other$27,225 (60.8%)
Research$6,513 (14.5%)
Education$5,000 (11.2%)
Consulting$4,815 (10.8%)
Travel$1,147 (2.6%)
Food & Beverage$91.42 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,225 | 5 | 60.8% |
| Unspecified | $6,513 | 24 | 14.5% |
| Education | $5,000 | 2 | 11.2% |
| Consulting Fee | $4,815 | 6 | 10.8% |
| Travel and Lodging | $1,147 | 3 | 2.6% |
| Food and Beverage | $91.42 | 3 | 0.2% |
Payments by Type
General
$38,279
19 transactions
Research
$6,513
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $35,658 | 11 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $8,513 | 27 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $545.96 | 3 | $0 (2017) |
| Daiichi Sankyo Inc. | $49.59 | 1 | $0 (2019) |
| Ipsen Biopharm Limited | $25.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,086 | 21 | Ipsen Biopharmaceuticals, Inc ($11,008) |
| 2023 | $20,051 | 9 | Ipsen Biopharmaceuticals, Inc ($18,975) |
| 2022 | $5,211 | 3 | Ipsen Biopharmaceuticals, Inc ($4,175) |
| 2021 | $1,677 | 3 | Ipsen Biopharmaceuticals, Inc ($1,500) |
| 2020 | $146.02 | 2 | Regeneron Pharmaceuticals, Inc. ($146.02) |
| 2019 | $74.59 | 2 | Daiichi Sankyo Inc. ($49.59) |
| 2017 | $545.96 | 3 | Alexion Pharmaceuticals, Inc. ($545.96) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 09/28/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $261.72 | Research |
| Study: REGN 2477 Clinical Development Program | ||||||
| 09/28/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $261.72 | Research |
| Study: REGN 2477 Clinical Development Program | ||||||
| 08/31/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $888.19 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 08/31/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $888.19 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 07/02/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $51.79 | Research |
| Study: REGN 2477 Clinical Development Program | ||||||
| 07/02/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $51.79 | Research |
| Study: REGN 2477 Clinical Development Program | ||||||
| 06/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $553.50 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 06/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $474.96 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 06/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $131.77 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 06/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $128.03 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 06/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $106.67 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 04/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $228.33 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 04/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $28.52 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 04/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $23.09 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 02/28/2024 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| 01/31/2024 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $16.83 | General |
| 01/30/2024 | Ipsen Biopharmaceuticals, Inc | Sohonos (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,650.00 | General |
| Category: Rare Disease | ||||||
| 01/30/2024 | Ipsen Biopharmaceuticals, Inc | Sohonos (Drug) | Travel and Lodging | In-kind items and services | $1,091.34 | General |
| Category: Rare Disease | ||||||
| 10/13/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $353.29 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 10/13/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $286.00 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
| 10/08/2023 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,000.00 | General |
| 06/18/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $148.27 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | Regeneron Pharmaceuticals, Inc. | $4,527 | 15 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | Regeneron Pharmaceuticals, Inc. | $1,036 | 1 |
| REGN 2477 Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $627.02 | 4 |
| GARETOSMAB CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $322.79 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 29 | 53 | $12,077 | $2,617 |
| 2022 | 1 | 18 | 39 | $10,452 | $2,182 |
| 2021 | 3 | 80 | 136 | $12,814 | $10,290 |
| 2020 | 2 | 63 | 135 | $12,235 | $9,609 |
Total Patients
190
Total Services
363
Medicare Billing
$24,698
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 25 | $6,925 | $1,544 | 22.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 28 | $5,152 | $1,073 | 20.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 39 | $10,452 | $2,182 | 20.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 42 | 87 | $8,743 | $7,026 | 80.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 30 | $2,096 | $1,702 | 81.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 19 | 19 | $1,975 | $1,561 | 79.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 69 | $7,137 | $5,780 | 81.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 33 | 66 | $5,098 | $3,829 | 75.1% |
About Dr. Robert Pignolo, MD
Dr. Robert Pignolo, MD is a Geriatric Medicine healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558302315.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Pignolo, MD has received a total of $44,792 in payments from pharmaceutical and medical device companies, with $17,086 received in 2024. These payments were reported across 43 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($27,225).
As a Medicare-enrolled provider, Pignolo has provided services to 190 Medicare beneficiaries, totaling 363 services with total Medicare billing of $24,698. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Other Specialties Internal Medicine
- Location Rochester, MN
- Active Since 06/10/2006
- Last Updated 08/02/2024
- Taxonomy Code 207RG0300X
- Entity Type Individual
- NPI Number 1558302315
Products in Payments
- Sohonos (Drug) $8,741
- SOLIRIS (Drug) $490.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Geriatric Medicine Doctors in Rochester
Eric Tangalos, M.d, M.D
Geriatric Medicine — Payments: $155,862
Geriatric Medicine $155,862
Malathy Sundaram, Md, MD
Geriatric Medicine — Payments: $2,180
Geriatric Medicine $2,180
Dr. Jad Sfeir, M.d, M.D
Geriatric Medicine — Payments: $1,767
Geriatric Medicine $1,767
Mr. Karun Badwal, D.o, D.O
Geriatric Medicine — Payments: $1,544
Geriatric Medicine $1,544
Maria Cynthia Enecilla, Md, MD
Geriatric Medicine — Payments: $1,190
Geriatric Medicine $1,190
Dr. Roksolana Kuchma, Md, MD
Geriatric Medicine — Payments: $855.29
Geriatric Medicine $855.29